HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J Slammed With Costliest Talc Verdict Yet; California Plaintiff Awarded $417M

This article was originally published in The Rose Sheet

Executive Summary

California could emerge as the new hub for talc litigation following a Los Angeles jury verdict awarding $417m in damages to a terminally ill plaintiff who linked her ovarian cancer to longtime use of J&J's talcum powder products.

You may also be interested in...

J&J’s Talc Winning Streak Continues With Calif. Mesothelioma Verdict

A California jury sided with J&J Nov. 16 in the first trial over whether alleged asbestos in the firm's talcum powders caused plaintiff's mesothelioma. The verdict could help check what threatens to be a new field of litigation against J&J for alleged talc dangers, and the firm also is gaining momentum in its defense against ovarian cancer claims.

Product Liability Litigation Playbook: Pros And Cons For Pharma

Drug makers are winning cases by getting expert testimony tossed, but the AndroGel verdict shows how narrow claims can benefit plaintiffs. The Pink Sheet offers a look at drugs in multidistrict litigation from Abilify to Zoloft.

J&J May Have Just Received Lifeline Out Of St. Louis Talc Tort Morass

A judge in the Missouri state court where J&J has suffered a series of hefty losses declared a mistrial June 19 in the latest talc-cancer case to be heard by jurors. The decision came two days after a US Supreme Court decision that also could trigger reversals of costly J&J verdicts currently under appeal.

Related Content


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts